Royalty Pharma plc 8-K

What Happened

• On April 13, 2026, Revolution Medicines announced positive Phase 3 RASolute 302 results for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), meeting primary and key secondary endpoints including progression‑free survival and overall survival. Revolution Medicines intends to submit these data to global regulators, including the FDA, as part of a future NDA under a Commissioner’s National Priority Voucher.
• Under a June 2025 agreement between Royalty Pharma and Revolution Medicines, Royalty Pharma committed up to $2.0 billion in combined synthetic royalty funding (up to $1.25 billion) and a senior secured loan (up to $750 million). Royalty Pharma funded $250 million upfront in June 2025 and the April 13 announcement triggered an additional $250 million draw, bringing total funded cash to $500 million to date.

Key Details

• $2.0 billion total agreement capacity: up to $1.25B synthetic royalty funding + up to $750M senior secured loan.
• $250M funded June 2025 (initial) + $250M funded April 13, 2026 (triggered) = $500M funded so far.
• Current royalty schedule (with second tranche): 4.55% on sales $0–$2B (and overlapping zoldonrasib), 2.50% on $2–$4B, 1.00% on $4–$8B.
• Additional $750M synthetic royalty funding available at Revolution’s option; if fully drawn, royalty rates would rise to 7.80% ($0–$2B), 4.55% ($2–$4B), 2.40% ($4–$8B). Senior loan of up to $750M is structured in three tranches; first $250M loan tranche required to be drawn upon FDA approval in metastatic PDAC.

Why It Matters

• For Royalty Pharma investors, the Phase 3 win materially advances the possibility of regulatory approval and commercial sales for daraxonrasib, and it already triggered additional funding under Royalty Pharma’s deal — increasing Royalty Pharma’s funded exposure and potential royalty revenue stream.
• The filing lays out specific royalty rates and loan terms tied to approval and sales milestones, showing clear upside if Revolution draws remaining funding and achieves approvals and sales; however, actual revenue depends on regulatory approvals, commercial launch, and sales performance. The 8‑K also includes standard forward‑looking disclaimers about risks and uncertainties.